Lee G. Giguere serves as Vice President, General Counsel, Secretary of the Company. Prior to joining the Company, he served as Deputy General Counsel and Assistant Secretary from July 2018 to September 2019 and Associate General Counsel and Assistant Secretary from September 2016 to July 2018 of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), an oncology-focused pharmaceutical company. Prior to joining Karyopharm Therapeutics Inc., Mr. Giguere was Senior Securities and Governance Counsel at Boston Scientific Corporation (NYSE: BSX), a Fortune 500 medical device company. Mr. Giguere began his professional career in the business law department of Goodwin Procter LLP where he concentrated his practice on representing public companies in connection with securities law and corporate governance matters and corporate finance transactions. Mr. Giguere received his B.S. in Finance from Northeastern University and his J.D. from Northeastern University School of Law.
As the Vice President, General Counsel, e Secretary of Chiasma Inc, the total compensation of Lee Giguere at Chiasma Inc is $499,517. There are 4 executives at Chiasma Inc getting paid more, with Raj Kannan having the highest compensation of $6,413,280.
Lee Giguere is 40, he's been the Vice President, General Counsel, e Secretary of Chiasma Inc since 2019. There are 12 older and no younger executives at Chiasma Inc. The oldest executive at Chiasma Inc is John Scarlett, 69, who is the Independent Director.
Lee's mailing address filed with the SEC is C/O CHIASMA, INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM, MA, 02494.
Over the last 9 years, insiders at Chiasma Inc have traded over $0 worth of Chiasma Inc stock and bought 324,855 units worth $2,372,906 . The most active insiders traders include Llp Abingworth, Ansbert Gadicke, eJohn F Thero. On average, Chiasma Inc executives and independent directors trade stock every 85 days with the average trade being worth of $94,895. The most recent stock trade was executed by Roni Mamluk on 9 February 2021, trading 27,981 units of CHMA stock currently worth $51,765.
Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Chiasma Inc executives and other stock owners filed with the SEC include: